1956 |
EPIDERMAL GROWTH FACTOR RECEPTOR |
EGFR |
ERBB |
ERBB1 |
HER1 |
NISBD2 |
PIG61 |
mENA |
131550 |
3236 |
ENSG00000146648 |
OTTHUMG00000023661 |
P00533 |
EGFR_HUMAN |
19 |
Proto-oncogene c-ErbB-1 |
Receptor tyrosine-protein kinase erbB-1 |
PA7360 |
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER4 (ERBB4) |
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3) |
EGFR (HER1/ERBB1) |
EPIDERMAL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P00533] |
T59328 |
ERRP |
CancerCommons Reported Gene Name | EGFR |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Target Subclass | Kinase |
Target Main Class | Receptors |
Transmembrane Helix Count | 1 |
Target Subclass | EGFR |
Initial Gene Query | EGFR |
Counted Citations from 1950-2000 | 12181 |
Human Readable Name | DRUGGABLE GENOME |
Interpro Type | Domain |
Interpro Acc | IPR001245 |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Uniprot Status | Swiss-Prot |
Human Readable Name | KINASE |
Gene Biotype | PROTEIN_CODING |
CELL SURFACE |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Clinical Status | NCCN/ CAP guidelines |
Clinical Status | early trials |
Variant Effect | gain-of-function |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
inhibitor (inhibitory) |
combination therapy | AZD9291 + JNJ-61186372 |
Approval Status | Preclinical - Cell line xenograft |
Approval Status | FDA approved |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | PF-299804 |
Indication/Tumor Type | non-small cell lung carcinoma |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | decreased response |
antibody (inhibitory) |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | HuMax-EGFr |
Notes |
antibody (inhibitory) |
Evidence Type | Actionable |
Response Type | predicted – sensitive |
Indication/Tumor Type | Advanced Solid Tumor |
n/a |
Trial Name | rindopepimut, CDX-110 |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
combination therapy | MGCD265 + Erlotinib |
Approval Status | Phase III |
combination therapy | AUY922 + Erlotinib |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
antibody (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | necitumumab , IMC-11F8 |
Novel drug target | Established target |
Notes |
antibody (inhibitory) |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Notes | |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | Advanced Solid Tumor |
antibody (inhibitory) |
Notes | |
Novel drug target | Established target |
Trial Name | Nimotuzumab |
inhibitor (inhibitory) |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Approval Status | Phase II |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Indication/Tumor Type | Advanced Solid Tumor |
inhibitor (inhibitory) |
Trial Name | AC480 |
Novel drug target | Established target |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
suppressor (inhibitory) |
antibody (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Trial Name | Iressa |
Novel drug target | Established target |
Indication/Tumor Type | colorectal cancer |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
antibody (inhibitory) |
Notes | |
Approval Status | Preclinical |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Response Type | sensitive |
combination therapy | Sapitinib + Paclitaxel |
Indication/Tumor Type | inflammatory breast carcinoma |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Evidence Type | Actionable |
Approval Status | Preclinical - Cell culture |
inhibitor (inhibitory) |
Trial Name | ARRY-334543 |
Novel drug target | Established target |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
inhibitor (inhibitory) |
Response Type | sensitive |
Indication/Tumor Type | squamous cell carcinoma |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | sensitive |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Reported Cancer Type | Lung, Prostate |
antibody (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 antagonist |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | predicted – sensitive |
Approval Status | Phase II |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | non-small cell lung carcinoma |
inhibitor (inhibitory) |
Notes | |
Approval Status | Phase I |
Response Type | sensitive |
inhibitor (inhibitory) |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | sensitive |
Approval Status | Phase II |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
Approval Status | Preclinical |
n/a |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 other |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | Zactima |
Novel drug target | Established target |
combination therapy | Vandetanib + Temozolomide |
inhibitor (inhibitory) |
Evidence Type | Actionable |
Approval Status | Preclinical |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
n/a |
combination therapy | Sapitinib + Paclitaxel |
Indication/Tumor Type | inflammatory breast carcinoma |
Response Type | sensitive |
antagonist (inhibitory) |
Trial Name | PSD502, lidocaine + prilocaine |
Novel drug target | Established target |
n/a |
combination therapy | MGCD265 + Erlotinib |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | predicted – sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor erbB1 inhibitor |
Direct Interaction | yes |
EGFR | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
EGFR | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
1956 | Entrez Gene ID |
CancerCommons Reported Gene Name | EGFR |
EGFR_HUMAN | Uniprot Id |
ENSG00000146648 | Ensembl Gene Id |
P00533 | Uniprot Accession |
Target Subclass | Kinase |
Target Main Class | Receptors |
Transmembrane Helix Count | 1 |
EGFR | Display Id |
ENSG00000146648 | Ensembl Gene Id |
EPIDERMAL GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1). [SOURCE:UNIPROT/SWISSPROT;ACC:P00533] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
1956 | Entrez Gene ID |
Initial Gene Query | EGFR |
Counted Citations from 1950-2000 | 12181 |
KINASE |
P00533 | Uniprot Accession |
1956 | Entrez Gene Id |
EGFR | Uniprot Gene Name |
Interpro Type | Domain |
Interpro Acc | IPR001245 |
Human Readable Name | DRUGGABLE GENOME |
KINASE, DRUGGABLE GENOME |
1956 | CKB Entrez Id |
EGFR | CKB Gene Synonym |
ERBB | CKB Gene Synonym |
PA7360 | PharmGKB ID |
1956 | Entrez Gene ID |
19 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
EGFR | TTD Gene Abbreviation |
T59328 | TTD Target ID |
HER1 | Gene Symbol |
EGFR | Gene Symbol |
ENSG00000146648 | Gene Symbol |
EGFR | Ensembl Id |
DRUGGABLE GENOME |
1956 | Entrez Gene Id |
EGFR | MyCancerGenome Gene Symbol |
EGFR (HER1/ERBB1) | MyCancerGenome Reported Gene Name |
ERBB1 | GENE_SYMBOL |
HER1 | GENE_SYMBOL |
EGFR | GENE_SYMBOL |
ERBB1 | OncoKB Gene Synonym |
1956 | OncoKB Entrez Id |
PIG61 | OncoKB Gene Synonym |
ERBB | GO Gene Synonym |
ERBB1 | GO Gene Synonym |
HER1 | GO Gene Synonym |
CELL SURFACE, TYROSINE KINASE |
EGFR | Gene Symbol |
CLINICALLY ACTIONABLE |
1956 | Gene ID |
ERBB | dGene Synonym |
ERBB1 | dGene Synonym |
KINASE, TYROSINE KINASE |
Epidermal growth factor receptor | Gene Name |
P00533 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |